Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons

Tobacco smoking is frequently abused by schizophrenia patients (SZP). The major synaptically active component inhaled from cigarettes is nicotine, hence the smoking habit of SZP may represent an attempt to use nicotine self-medication to correct (i) a central nervous system nicotinic acetylcholine receptor (nAChR) dysfunction, (ii) DNA-methyltransferase 1 (DMT1) overexpression in GABAergic neurons, and (iii) the down-regulation of reelin and GAD67 expression caused by the increase of DNMT1-mediated hypermethylation of promoters in GABAergic interneurons of the telencephalon. Nicotine (4.5–22 μmol/kg s.c., 4 injections during the 12-h light cycle for 4 days) decreases DNMT1 mRNA and protein and increases GAD67 expression in the mouse frontal cortex (FC). This nicotine-induced decrease of DNMT1 mRNA expression is greater (80%) in laser microdissected FC layer I GABAergic neurons than in the whole FC (40%), suggesting selectivity differences for the specific nicotinic receptor populations expressed in GABAergic neurons of different cortical layers. The down-regulation of DNMT1 expression induced by nicotine in the FC is also observed in the hippocampus but not in striatal GABAergic neurons. Furthermore, these data show that in the FC, the same doses of nicotine that decrease DNMT1 expression also (i) diminished the level of cytosine-5-methylation in the GAD67 promoter and (ii) prevented the methionine-induced hypermethylation of the same promoter. Pretreatment with mecamylamine (6 μmol/kg s.c.), an nAChR blocker that penetrates the blood–brain barrier, prevents the nicotine-induced decrease of FC DNMT1 expression. Taken together, these results suggest that nicotine, by activating nAChRs located on cortical or hippocampal GABAergic interneurons, can up-regulate GAD67 expression via an epigenetic mechanism. Nicotine is not effective in striatal medium spiny GABAergic neurons that primarily express muscarinic receptors.

[1]  A. Guidotti,et al.  Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation , 2008, Proceedings of the National Academy of Sciences.

[2]  Nucleic acid quantitation using the competitive polymerase chain reaction , 2007 .

[3]  B. Roth,et al.  UC San Francisco UC San Francisco Previously Published Works Title The pipeline and future of drug development in schizophrenia , 2008 .

[4]  Khosrow Rezvani,et al.  Nicotine Regulates Multiple Synaptic Proteins by Inhibiting Proteasomal Activity , 2007, The Journal of Neuroscience.

[5]  Benjamin W. H. Lim,et al.  Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars , 2007, Proceedings of the National Academy of Sciences.

[6]  J. Changeux,et al.  Long-term effects of chronic nicotine exposure on brain nicotinic receptors , 2007, Proceedings of the National Academy of Sciences.

[7]  A. Guidotti,et al.  Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection , 2007, Molecular Psychiatry.

[8]  A. Guidotti,et al.  Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters , 2007, Proceedings of the National Academy of Sciences.

[9]  E. Costa,et al.  Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder , 2007, Schizophrenia Research.

[10]  R. Tyndale,et al.  Inhibition of Nicotine Metabolism by Methoxysalen: Pharmacokinetic and Pharmacological Studies in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  Brandon J. Margolis,et al.  Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. , 2006, Bioorganic & medicinal chemistry.

[12]  P. Szekeres,et al.  Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat , 2006, Psychopharmacology.

[13]  A. Guidotti,et al.  Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Guidotti,et al.  GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon , 2005, Psychopharmacology.

[15]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[16]  A. Guidotti,et al.  Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice , 2005, Biological Psychiatry.

[17]  Robert Freedman,et al.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia , 2004, Psychopharmacology.

[18]  Charles J. Wilson,et al.  Cholinergic interneuron characteristics and nicotinic properties in the striatum. , 2002, Journal of neurobiology.

[19]  D. Brunzell,et al.  Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. , 2001, Pharmacology & therapeutics.

[20]  B. de Strooper,et al.  The amyloid precursor protein (APP)‐cytoplasmic fragment generated by γ‐secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture , 2001, Journal of neurochemistry.

[21]  B. Kolb,et al.  Nicotine sensitization increases dendritic length and spine density in the nucleus accumbens and cingulate cortex , 2001, Brain Research.

[22]  Nicholas Lange,et al.  Two-dimensional versus three-dimensional cell counting: a practical perspective , 2001, Trends in Neurosciences.

[23]  E. Albuquerque,et al.  Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus , 2000, Neuropharmacology.

[24]  A. Köfalvi,et al.  Long-lasting facilitation of 4-amino-n-[2,3-(3)H]butyric acid ([(3)H]GABA) release from rat hippocampal slices by nicotinic receptor activation. , 2000, The Journal of pharmacology and experimental therapeutics.

[25]  Yogesh K. Dwivedi,et al.  Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. , 2000, Archives of general psychiatry.

[26]  A. C. Collins,et al.  Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with Schizophrenia , 2000, Neuropsychopharmacology.

[27]  H. Mansvelder,et al.  Long-Term Potentiation of Excitatory Inputs to Brain Reward Areas by Nicotine , 2000, Neuron.

[28]  D. Ji,et al.  Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. , 2000, Journal of neurophysiology.

[29]  J. Gault,et al.  Smoking and schizophrenia: abnormal nicotinic receptor expression. , 2000, European journal of pharmacology.

[30]  A. Bird.  DNA Methylation de Novo , 1999, Science.

[31]  John T. Williams,et al.  Nicotine activates and desensitizes midbrain dopamine neurons , 1997, Nature.

[32]  S. Akbarian,et al.  GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. , 1995, Cerebral cortex.

[33]  A. C. Collins,et al.  Mecamylamine blockade of nicotine responses: Evidence for two brain nicotinic receptors , 1986, Pharmacology Biochemistry and Behavior.

[34]  G. Higgins,et al.  Mediation of nicotine-induced convulsions by central nicotinic receptors of the ‘C6’ type , 1983, Neuropharmacology.

[35]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .